|
시장보고서
상품코드
2076011
네오스티그민 메틸황산염 주사액 시장 : 투여량별, 적응증별, 유통 채널별, 최종 용도별, 지역별Neostigmine Methylsulfate Injection Market, By Dosage, By Indication, By Distribution Channel, By End Use, By Geography |
||||||
네오스티그민 메틸황산염 주사액 시장은 2026년에 1억 7,960만 달러 규모가 된다고 추정되고 있어 2033년까지 2억 4,760만 달러에 이를 것으로 예상되고 있습니다. 2026년부터 2033년까지 CAGR 4.7%로 성장할 전망입니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도 : | 2025년 | 2026년 시장 규모 : | 1억 7,960만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 2026-2033년 예측 기간 CAGR : | 4.70% | 2033년 시장 규모 예측 : | 2억 4,760만 달러 |
네오스티그민 메틸황산염 주사액은 중증근무력증 치료의 보조제로, 또한 수술실이나 중환자실(ICU)에서 비탈분극성 신경근 차단제 중독에 대한 해독제로 사용되는 콜린에스테라제 억제제입니다. 이 약은 일반적으로 신경근 접합부에서 신경전달물질인 아세틸콜린을 분해하는 아세틸콜린에스테라제 효소를 억제함으로써 작용합니다. 이 효소를 억제함으로써, 네오스티그민 메틸황산염은 아세틸콜린의 작용 시간을 연장하고, 신경근 전달과 근력을 향상시킵니다. 이 약은 사지, 몸통, 인후 및 눈의 골격근 근력 저하 등 중증근무력증의 증상 관리에 도움이 됩니다. 과다 투여 시나 민감도가 높은 환자의 경우, 신경근 접합부에서의 자극이 강화되어 메스꺼움, 타액 분비 증가, 근육 경련 등의 부작용이 발생할 수 있습니다.
시장 역학:
고령 인구 증가는 예측 기간 동안 전 세계 네오스티그민 메틸황산염 주사액 시장의 성장을 지속적으로 견인할 것입니다. 고령자는 중증근무력증과 같은 신경 질환에 걸리기 쉬우며, 그 치료에는 네오스티그민 메틸황산염 주사가 자주 필요합니다. 의료비 증가 역시 예측 기간 동안 전 세계 네오스티그민 메틸황산염 주사액 시장의 성장을 지속적으로 견인할 것으로 보입니다. 수의학 분야의 성장은 예측 기간 동안 전 세계 네오스티그민 메틸황산염 주사액 시장에 새로운 기회를 가져다줄 것입니다. 네오스티그민 메틸황산염 주사액는 수의학 분야, 특히 동물의 일부 신경근 질환 치료에도 사용되고 있습니다. 이를 통해 수의학 분야에서 네오스티그민 메틸황산염 주사액의 사용 및 입수 가능성을 높일 수 있는 새로운 상업적 전망이 열릴 가능성이 있습니다.
지식과 진단 역량의 부족으로 인해, 예측 기간 동안 전 세계 네오스티그민 메틸황산염 주사액 시장의 성장이 저해될 것으로 예측됩니다.
본 조사의 주요 특징:
- 본 조사에서는 다양한 부문에서 잠재적인 수익 성장 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한, 본 조사에서는 시장 성장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 그리고 주요 기업들이 채택하는 경쟁 전략에 관한 중요한 인사이트를 제공합니다.
- 본 조사에서는 다음의 매개변수(기업 개요, 제품 포트폴리오, 주요 하이라이트, 재무 실적, 전략)를 바탕으로 전 세계 네오스티그민 메틸황산염 주사액 시장의 주요 기업 프로파일을 작성하고 있습니다.
- 본 조사에서 다룬 주요 기업으로는 박스터 인터내셔널, 화이자, 프레제니우스 카비, 베링거 인겔하임, 마일란, 노바티스 인터내셔널, 테바 제약, 히쿠마 파마슈티컬스, 글락소 스미스클라인, 선 파마슈티컬 인더스트리즈, 산도즈(노바티스의 사업 부문), 어코드 헬스케어, 라넷 컴퍼니, 마린클로드 파마슈티컬스, 그리고 루핀 리미티드 등이 있습니다.
- 본 보고서에서 얻을 수 있는 인사이트는 각 기업의 마케팅 담당자 및 경영진이 향후 제품 출시, 제품 개선, 시장 확대 및 마케팅 전략에 관해 충분한 정보를 바탕으로 의사결정을 내리는 데 도움이 됩니다.
- 세계 네오스티그민 메틸황산염 주사액 시장에 관한 본 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진출기업, 금융 애널리스트 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 전 세계 네오스티그민 메틸황산염 주사액 시장 분석에 활용되는 다양한 전략 매트릭스를 활용함으로써 의사결정을 원활하게 진행할 수 있을 것입니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 전망
제3장 시장 역학, 규제 및 동향 분석
제4장 세계의 네오스티그민 메틸황산염 주사액 시장
제5장 세계의 네오스티그민 메틸황산염 주사액 시장 : 투여량별, 2021-2033년
제6장 세계의 네오스티그민 메틸황산염 주사액 시장 : 적응증별, 2021-2033년
제7장 세계의 네오스티그민 메틸황산염 주사액 시장 : 유통 채널별, 2021-2033년
제8장 세계의 네오스티그민 메틸황산염 주사액 시장 : 최종 사용자별, 2021-2033년
제9장 세계의 네오스티그민 메틸황산염 주사액 시장 : 지역별, 2021-2033년
제10장 경쟁 구도
제11장 섹션
JHS 26.07.09Neostigmine Methylsulfate Injection Market is estimated to be valued at USD 179.6 Mn in 2026 and is expected to reach USD 247.6 Mn by 2033, growing at a compound annual growth rate (CAGR) of 4.7% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 179.6 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 4.70% | 2033 Value Projection: | USD 247.6 Mn |
Neostigmine methylsulfate injection is a cholinesterase inhibitor that is used as an adjunct in the treatment of myasthenia gravis and as an antidote in the treatment of non-depolarizing neuromuscular blocking agent toxicity in the operating room or intensive care unit setting. It acts by inhibiting the acetylcholinesterase enzyme, which normally breaks down the neurotransmitter acetylcholine at the neuromuscular junction. By inhibiting this enzyme, neostigmine methylsulfate prolongs the actions of acetylcholine, increasing neuromuscular transmission and muscle strength. It helps in the management of myasthenia gravis symptoms such as weakness of the skeletal muscles of the extremities, trunk, throat, and eyes. In overdose or sensitive patients, it can cause increased stimulation at the neuromuscular junction and produce side effects such as nausea, increased saliva, and muscle cramps.
Market Dynamics:
The increasing geriatric population will continue to fuel the growth of the global neostigmine methylsulfate injection market over the forecast period. The elderly are more susceptible to neurological conditions like myasthenia gravis, which frequently needs to be treated with injections of neostigmine methylsulfate. Rising medical expenditures will also continue to fuel the growth of the global neostigmine methylsulfate injection market over the forecast period. The growth of veterinary medicine will create new opportunities for the global neostigmine methylsulfate injection market over the forecast period. Injections of neostigmine methylsulfate are also employed in veterinary medicine, particularly for the treatment of a few neuromuscular diseases in animals. It may open up new commercial prospects to increase the use and availability of neostigmine methylsulfate injections in the veterinary industry.
Lack of knowledge and diagnosis is expected to hamper the growth of the global neostigmine methylsulfate injection market over the forecast period.
Key Features of the Study:
- It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global neostigmine methylsulfate injection market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- The key companies covered as a part of this study include Baxter International Inc., Pfizer Inc., Fresenius Kabi AG, Boehringer Ingelheim GmbH, Mylan N.V., Novartis International AG, Teva Pharmaceutical Industries Ltd., Hikma Pharmaceuticals PLC, GlaxoSmithKline plc, Sun Pharmaceutical Industries Ltd., Sandoz (a division of Novartis), Accord Healthcare Inc., Lannett Company, Inc., Mallinckrodt Pharmaceuticals, and Lupin Limited
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global neostigmine methylsulfate injection market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global neostigmine methylsulfate injection market
Detailed Segmentation:
- Global Neostigmine Methylsulfate Injection Market, By Dosage:
- 1 mg/mL
- 0.5 mg/mL
- Global Neostigmine Methylsulfate Injection Market, By Indications:
- Myasthenia Gravis
- Reversal of Neuromuscular Blockade
- Global Neostigmine Methylsulfate Injection Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Neostigmine Methylsulfate Injection Market, By End User:
- Hospitals
- Specialty Clinics
- Ambulatory Surgical Centers
- Regional Insights (Revenue, USD Mn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Company Profile:
- Baxter International Inc.
- Pfizer Inc.
- Fresenius Kabi AG
- Boehringer Ingelheim GmbH
- Mylan N.V.
- Novartis International AG
- Teva Pharmaceutical Industries Ltd.
- Hikma Pharmaceuticals PLC
- GlaxoSmithKline plc
- Sun Pharmaceutical Industries Ltd.
- Sandoz (a division of Novartis)
- Accord Healthcare Inc.
- Lannett Company, Inc.
- Mallinckrodt Pharmaceuticals
- Lupin Limited
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Neostigmine Methylsulfate Injection Market, By Dosage
- Neostigmine Methylsulfate Injection Market, By Indication
- Neostigmine Methylsulfate Injection Market, By Distribution Channel
- Neostigmine Methylsulfate Injection Market, By End User
- Neostigmine Methylsulfate Injection Market, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Rising prevalence of diseases like myasthenia gravis and postoperative ileus requiring neostigmine
- Restraints
- Lack of knowledge and diagnosis
- Opportunities
- Growth of veterinary medicine
- Drivers
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER€(TM)s Analysis
- Merger and Acquisition Scenario
4. Global Neostigmine Methylsulfate Injection Market
- Supply Side and Demand Side Analysis
- Economic Impact
5. Global Neostigmine Methylsulfate Injection Market, By Dosage, 2021 - 2033, (US$ Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- 1 mg/mL
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
- 0.5 mg/mL
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
6. Global Neostigmine Methylsulfate Injection Market, By Indication, 2021 - 2033, (US$ Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Myasthenia Gravis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
- Reversal of Neuromuscular Blockade
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
7. Global Neostigmine Methylsulfate Injection Market, By Distribution Channel, 2021 - 2033, (US$ Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
8. Global Neostigmine Methylsulfate Injection Market, By End User, 2021 - 2033, (US$ Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
- Specialty Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
- Ambulatory Surgical Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
9. Global Neostigmine Methylsulfate Injection Market, By Region, 2021 - 2033, (US$ Mn)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Region 2022 - 2033
- Country Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Dosage, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(US$ Mn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Dosage, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(US$ Mn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Dosage, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(US$ Mn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Dosage, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East & Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Dosage, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(US$ Mn)
- GCC
- Israel
- Rest of Middle East
- North Africa
- Central Africa
- South Africa
10. Competitive Landscape
- Baxter International Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Fresenius Kabi AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Boehringer Ingelheim GmbH
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Mylan N.V.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Novartis International AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Hikma Pharmaceuticals PLC
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- GlaxoSmithKline plc
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Sun Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Sandoz (a division of Novartis)
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Accord Healthcare Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Lannett Company, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Mallinckrodt Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Lupin Limited
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Analyst Views
11. Section
- Research Methodology
- About us
